Merck’s Profit Beats Estimates on Diabetes Drug Sales

  • Hepatitis C drug Zepatier is growing, gaining access
  • Sales of newly launched cancer drug Keytruda almost triples

Merck & Co.’s second-quarter profit topped analysts’ estimates, led by sales growth from its diabetes drug Januvia and newly introduced cancer treatment Keytruda.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.